122 related articles for article (PubMed ID: 29789103)
21. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.
Cullen JM; Li DH; Brown C; Eisenberg EJ; Cundy KC; Wolfe J; Toole J; Gibbs C
Antimicrob Agents Chemother; 2001 Oct; 45(10):2740-5. PubMed ID: 11557463
[TBL] [Abstract][Full Text] [Related]
22. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2).
Annaert P; Kinget R; Naesens L; de Clercq E; Augustijns P
Pharm Res; 1997 Apr; 14(4):492-6. PubMed ID: 9144737
[TBL] [Abstract][Full Text] [Related]
23. Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.
Lin CC; Yeh LT; Vitarella D; Hong Z; Erion MD
Antivir Chem Chemother; 2004 Nov; 15(6):307-17. PubMed ID: 15646644
[TBL] [Abstract][Full Text] [Related]
24. Adefovir dipivoxil in chronic hepatitis B: history and current uses.
Segovia MC; Chacra W; Gordon SC
Expert Opin Pharmacother; 2012 Feb; 13(2):245-54. PubMed ID: 22242973
[TBL] [Abstract][Full Text] [Related]
25. Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose?
Law ST; Li KK; Ho YY
J Clin Pharm Ther; 2012 Apr; 37(2):128-31. PubMed ID: 21714795
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment.
Shiffman ML; Pol S; Rostaing L; Schiff E; Thabut D; Zeuzem S; Zong J; Frederick D; Rousseau F
J Clin Pharmacol; 2011 Sep; 51(9):1293-301. PubMed ID: 20978280
[TBL] [Abstract][Full Text] [Related]
27. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Shaw JP; Sueoko CM; Oliyai R; Lee WA; Arimilli MN; Kim CU; Cundy KC
Pharm Res; 1997 Dec; 14(12):1824-9. PubMed ID: 9453075
[TBL] [Abstract][Full Text] [Related]
28. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
[No Abstract] [Full Text] [Related]
29. Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells.
Maeng HJ; Chapy H; Zaman S; Pang KS
Eur J Pharm Sci; 2012 Jun; 46(3):149-66. PubMed ID: 22387228
[TBL] [Abstract][Full Text] [Related]
30. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.
Jonas MM; Kelly D; Pollack H; Mizerski J; Sorbel J; Frederick D; Mondou E; Rousseau F; Sokal E
Hepatology; 2008 Jun; 47(6):1863-71. PubMed ID: 18433023
[TBL] [Abstract][Full Text] [Related]
31. Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release.
Du L; Wu L; Jin Y; Jia J; Li M; Wang Y
Int J Pharm; 2014 Sep; 472(1-2):1-9. PubMed ID: 24929012
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA.
Van Gelder J; Witvrouw M; Pannecouque C; Henson G; Bridger G; Naesens L; De Clercq E; Annaert P; Shafiee M; Van den Mooter G; Kinget R; Augustijns P
Int J Pharm; 1999 Sep; 186(2):127-36. PubMed ID: 10486430
[TBL] [Abstract][Full Text] [Related]
33. Stabilized oral nanostructured lipid carriers of Adefovir Dipivoxil as a potential liver targeting: Estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator.
Abd El-Halim SM; Abdelbary GA; Amin MM; Zakaria MY; Shamsel-Din HA; Ibrahim AB
Daru; 2020 Dec; 28(2):517-532. PubMed ID: 32564282
[TBL] [Abstract][Full Text] [Related]
34. Permeation enhancer dodecyl 6-(dimethylamino)hexanoate increases transdermal and topical delivery of adefovir: influence of pH, ion-pairing and skin species.
Vávrová K; Lorencová K; Novotný J; Holý A; Hrabálek A
Eur J Pharm Biopharm; 2008 Nov; 70(3):901-7. PubMed ID: 18675907
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study.
Van Gelder J; Annaert P; Naesens L; De Clercq E; Van den Mooter G; Kinget R; Augustijns P
Pharm Res; 1999 Jul; 16(7):1035-40. PubMed ID: 10450927
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir.
Fu XZ; Ou Y; Pei JY; Liu Y; Li J; Zhou W; Lan YY; Wang AM; Wang YL
Eur J Med Chem; 2012 Mar; 49():211-8. PubMed ID: 22305613
[TBL] [Abstract][Full Text] [Related]
37. Adefovir dipivoxil in the treatment of chronic hepatitis B.
Rivkin AM
Ann Pharmacother; 2004 Apr; 38(4):625-33. PubMed ID: 14990784
[TBL] [Abstract][Full Text] [Related]
38. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Westland CE; Yang H; Delaney WE; Gibbs CS; Miller MD; Wulfsohn M; Fry J; Brosgart CL; Xiong S;
Hepatology; 2003 Jul; 38(1):96-103. PubMed ID: 12829991
[TBL] [Abstract][Full Text] [Related]
39. [Design, synthesis and anti-hBV evaluation of adefovir mono-L-amino acid ester, mono non-steroidal anti-inflammatory drugs carboxylic ester prodrugs].
Fu XZ; Wang YL; Lan YY; Wang AM; Ou Y; Luo C; Li Y
Yao Xue Xue Bao; 2010 Aug; 45(8):1017-24. PubMed ID: 21351588
[TBL] [Abstract][Full Text] [Related]
40. Absence of a pharmacokinetic interaction between entecavir and adefovir.
Bifano M; Yan JH; Smith RA; Zhang D; Grasela DM; LaCreta F
J Clin Pharmacol; 2007 Oct; 47(10):1327-34. PubMed ID: 17675455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
